文献速递肝病消化道肿瘤与早癌

肝细胞癌细胞上调PVRL1稳定PVR并通过TIGIT抑制细胞毒性T细胞应答介导小鼠对PD1抑制剂耐药

Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
PubMed 文献 · Gastroenterology · 2020-04-08

该研究在小鼠肝细胞癌模型中探索PD1抑制剂耐药机制,发现肿瘤细胞上调PVRL1稳定细胞表面PVR,与CD8+效应记忆T细胞上的TIGIT结合抑制抗肿瘤免疫。联合阻断PD1和TIGIT可显著抑制肿瘤生长并延长生存。

要点

  • HCC细胞上调PVRL1,稳定细胞表面PVR,与TIGIT结合抑制CD8+ T细胞应答。
  • PVRL1高表达与患者无病生存期缩短相关。
  • 联合抗PD1和抗TIGIT可增强抗肿瘤免疫并延长小鼠生存。

核心结论

  • HCC细胞上调PVRL1稳定细胞表面PVR,与CD8+效应记忆T细胞上的TIGIT结合抑制抗肿瘤免疫,介导对PD1抑制剂耐药。

研究设计与样本

  • 研究使用Trp53KO/C-MycOE小鼠模型和Hepa1-6细胞注射C57BL/6小鼠肝内模型,并分析香港手术患者HCC组织。

主要发现

  • Trp53KO/C-MycOE小鼠3-5周发生肝肿瘤,抗PD1注射未减缓肿瘤发展。
  • 抗PD1处理小鼠肿瘤中记忆CD8+ T细胞(CD44+CD62L-KLRG1int)及表达PD1、LAG3和TIGIT的T细胞数量增多。
  • 患者HCC组织中PVRL1 mRNA和蛋白水平高于非肿瘤组织,PVRL1升高与无病生存期缩短相关。
  • 敲低Hepa1-6细胞Pvrl1后小鼠肿瘤变小,浸润CD8+ T细胞(表达TIGIT)增多,该效应在清除CD8+ T细胞后消失。
  • PVRL1稳定细胞表面PVR,敲低Pvrl1降低细胞表面PVR但不影响Pvr mRNA水平。

临床怎么用

  • PVRL1/TIGIT通路可能作为HCC对PD1抑制剂耐药的标志和联合治疗靶点。

局限性

  • 研究主要基于小鼠模型和有限患者组织,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Immune checkpoint inhibitors are effective in the treatment of some hepatocellular carcinomas (HCCs), but these tumors do not always respond to inhibitors of programmed cell death 1 (PDCD1, also called PD1). We investigated mechanisms of resistance of liver tumors in mice to infiltrating T cells. METHODS: Mice were given hydrodynamic tail vein injections of clustered regularly interspaced short palindromic repeats-Cas9 (CRISPR-Cas9) and transposon vectors to disrupt Trp53 and overexpress C-Myc (Trp53KO/C-MycOE mice). Pvrl1 and Pvrl3 were knocked down in Hepa1-6 cells by using short hairpin RNAs. Hepa1-6 cells were injected into livers of C57BL/6 mice; some mice were given intraperitoneal injections of antibodies against PD1, T-cell immunoreceptor with Ig and ITIM domains (TIGIT), or CD8 before the cancer cells were injected. Liver tissues were collected from mice and analyzed by histology, immunohistochemistry, and quantitative real-time polymerase chain reaction; tumors were analyzed by mass cytometry using markers to detect T cells and other lymphocytes. We obtained HCC and nontumorous liver tissues and clinical data from patients who underwent surgery in Hong Kong and analyzed the tissues by immunohistochemistry. RESULTS: Trp53KO/C-MycOE mice developed liver tumors in 3-5 weeks; injections of anti-PD1 did not slow tumor development. Tumors from mice given anti-PD1 had larger numbers of memory CD8+ T cells (CD44+CD62L-KLRG1int) and T cells that expressed PD1, lymphocyte activating 3 (LAG3), and TIGIT compared with mice not given the antibody. HCC tissues from patients had higher levels of PVRL1 messenger RNA and protein than nontumorous tissues. Increased PVRL1 was associated with shorter times of disease-free survival. Knockdown of Pvrl1 in Hepa1-6 cells caused them to form smaller tumors in mice, infiltrated by higher numbers of CD8+ T cells that expressed the inhibitory protein TIGIT; these effects were not observed in mice with depletion of CD8+ T cells. In Hepa1-6 cells, PVRL1 stabilized cell surface PVR, which interacted with TIGIT on CD8+ T cells; knockdown of Pvrl1 reduced cell-surface levels of PVR but not levels of Pvr messenger RNA. In Trp53KO/C-MycOE mice and mice with tumors grown from Hepa1-6 cells, injection of the combination of anti-PD1 and anti-TIGIT significantly reduced tumor growth, increased the ratio of cytotoxic to regulatory T cells in tumors, and prolonged survival. CONCLUSIONS: PVRL1, which is up-regulated by HCC cells, stabilizes cell surface PVR, which interacts with TIGIT, an inhibitory molecule on CD8+ effector memory T cells. This suppresses the ant-tumor immune response. Inhibitors of PVRL1/TIGIT, along with anti-PD1 might be developed for treatment of HCC.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Chiu DK, Yuen VW, Cheu JW, et al. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. Gastroenterology. 2020. PMID: 32275969. doi:10.1053/j.gastro.2020.03.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。